Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello, Renzo, Piga, Antonio, Forni, Gian Luca, Bertrand, Yves, Foschini, Maria Loreta, Bordone, Elena, Leoni, Giovanbattista, Lavagetto, Antonella, Zappu, Antonietta, Longo, Filomena, Maseruka, Henry, Hewson, Nicola, Sechaud, Romain, Belleli, Rossella and Alberti, Daniele (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 91 (10). pp. 1343-1351. ISSN 1592-8721
Abstract
Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. This study evaluated the safety and tolerability of deferasirox in pediatric patients with transfusion-dependent beta-thalassemia major. Efficacy and pharmacokinetic assessments were secondary objectives.
Item Type: | Article |
---|---|
Related URLs: | |
Related URLs: | |
Date Deposited: | 05 Oct 2012 23:45 |
Last Modified: | 05 Oct 2012 23:45 |
URI: | https://oak.novartis.com/id/eprint/8695 |